Home / Research Library / Adjuvant atezolizumab after adjuvant chemotherapy...
🧬 Medicine & Biology OpenAlex

Adjuvant atezolizumab after adjuvant chemotherapy in resected stage IB–IIIA non-small-cell lung cancer (IMpower010): a randomised, multicentre, open-label, phase 3 trial

📅 September 20, 2021 👤 Enriqueta Felip, Nasser K. Altorki, Caicun Zhou et al. 📖 The Lancet 📊 1,473 citations

🤖 Plain-English Summary

This research explores Adjuvant atezolizumab after adjuvant chemotherapy in resecte..., contributing new insights to the field of Medicine & Biology.

🔑 Key Findings

  • Research demonstrates significant advances in patient outcome data
  • Study provides new evidence regarding clinical efficacy results
  • Findings open new directions for biological mechanism insights

💡 Why This Matters

Understanding this could lead to better treatments, improved diagnostics, or a deeper grasp of how the human body works — benefiting patient care globally.

Read the full paper
Access the original peer-reviewed research via OpenAlex.

View on DOI ↗

📋 Article Details

Category 🧬 Medicine & Biology
Published Sep 20, 2021
Journal The Lancet
Authors Enriqueta Felip, Nasser K. Altorki, Caicun Zhou, Tibor Csőszi, Ihor Vynnychenko
DOI 10.1016/s0140-6736(21)02098-5
Citations 1,473
Source OpenAlex

More 🧬 Medicine & Biology Research